U.S. Preventive Services Task Force banner
U.S. Preventive Services Task Force

You Are Here: U.S. Preventive Services Task Force > Topic Index > Menopausal Hormone Therapy > Recommendation Statement


Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions

Table 1. Estimated Event Rate Differences Associated With the Use of Oral Estrogen and Progestin in Postmenopausal Women Compared With No Treatment

Outcome Event Rate Difference per 10,000 Person-Years
Events Prevented, n (95% CI) Events Caused, n (95% CI)
Benefits
Total fractures 46 (29 to 63)
   Hip fracture 6 (1 to 10)
Harms
Stroke 9 (2 to 15)
Deep venous thrombosis 12 (6 to 17)
Pulmonary embolism 9 (4 to 14)
Invasive breast cancer incidence 8 (3 to 14)
Gallbladder disease 20 (11 to 29)
Dementia 22 (5 to 39)
Self-reported urinary incontinence 872 (591 to 1153)

Return to Document

Table 2. Estimated Event Rate Differences Associated With the Use of Unopposed Oral Estrogen in Postmenopausal Women Without a Uterus Compared With No Treatment

Outcome Event Rate Difference per 10,000 Person-Years
Events Prevented, n (95% CI) Events Caused, n (95% CI)
Benefits
Invasive breast cancer incidence 8 (1 to 14)
Breast cancer deaths 2 (1 to 3)
Total fractures 56 (37 to 75)
   Hip fracture 7 (1 to 12)
Harms
Stroke 11 (2 to 20)
Deep venous thrombosis 7 (1 to 14)
Gallbladder disease 33 (20 to 45)
Self-reported urinary incontinence 1271 (883 to 1660)

Return to Document

 


USPSTF Program Office   540 Gaither Road, Rockville, MD 20850